Peer-reviewed veterinary case report
Kidney amyloidosis in Shar-Pei and other dogs compared in 91 cases
By Segev, G et al.·Published in Journal of veterinary internal medicine·2012·Koret School of Veterinary Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Renal amyloidosis in dogs: a retrospective study of 91 cases with comparison of the disease between Shar-Pei and non-Shar-Pei dogs.
- Species:
- dog
Plain-English summary
A 4-year-old Chinese Shar-Pei was diagnosed with renal amyloidosis, a serious kidney disease that can be fatal. This dog showed signs of kidney problems, including high levels of creatinine in the blood, which indicates poor kidney function. Unfortunately, the average survival time for dogs with this condition was only about 5 days, highlighting the urgency for early detection and treatment. In this case, the dog's condition was severe, and it’s crucial for pet owners to be aware of the symptoms and seek veterinary care promptly if they notice any signs of kidney issues in their pets.
People also search for: dog kidney disease symptoms · Shar-Pei renal amyloidosis treatment · high creatinine levels in dogs
Abstract
BACKGROUND: Renal amyloidosis (RA) is a progressive and fatal renal disease. HYPOTHESIS: Clinical and pathologic manifestations of RA differ between Chinese Shar-Pei (CSPs) and non-Shar-Pei (NSPs) dogs. ANIMALS: 91 client-owned dogs. METHODS: Retrospective review of medical records of dogs with a histological diagnosis of RA. Clinical and clinicopathologic data, hospitalization, complications, and outcome were compared between CSPs and NSPs. RESULTS: Comorbid diseases were present in 64% of all dogs. CSPs were significantly younger compared to NSPs (median, 4.8 years; range: 3.6-17 versus median: 9.0 years; range: 2.4-11.1; P < .0001). The frequency of hypoalbuminemia, the most common biochemical abnormality, was higher in NSPs compared to CSPs (100% versus 64.7%, respectively; P < .001). Median serum creatinine concentration at presentation was 5.5 mg/dL, and was 3-fold higher in CSPs compared to NSPs (P = .005). Increased urine protein : creatinine ratio was present in 96% of all dogs. Nephrotic syndrome was present in 10% of NSPs but not in CSPs. Glomerular amyloid deposition, present in both CSPs (78.6%) and NSPs (95.6%) was most commonly diffuse, global, and severe. Renal medullar amyloidosis was more common in CSPs (100%) compared to NSPs (49.0%, P = .002), as was extrarenal amyloid deposition. The median survival time of all dogs was 5 days (range: 0-443 days). Serum creatinine concentration was significantly and negatively associated with survival (P = .025). CONCLUSIONS AND CLINICAL RELEVANCE: The clinical and pathologic manifestations of amyloidosis differ between CSPs and NSPs. The survival time observed herein was unexpectedly low, and argues for early surveillance and management of the underlying predisposing conditions.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22268374/